Exagen Inc Stock Performance
| XGN Stock | USD 3.64 0.02 0.55% |
The firm shows a Beta (market volatility) of 2.3, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Exagen will likely underperform. At this point, Exagen Inc has a negative expected return of -0.12%. Please make sure to confirm Exagen's jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to decide if Exagen Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Exagen Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
Five Day Return 9.37 | Year To Date Return 17.15 | Ten Year Return (80.52) | All Time Return (80.52) |
1 | FY2024 EPS Estimates for Exagen Lowered by Cantor Fitzgerald - MarketBeat | 01/23/2025 |
2 | Disposition of 4322 shares by Rocca Fortunato R. of Exagen at 7.12 subject to Rule 16b-3 | 01/28/2025 |
3 | Exagen Inc. to Participate in Upcoming Investor Conferences | 02/04/2025 |
4 | Strength Seen in Exagen Can Its 29.4 percent Jump Turn into More Strength - MSN | 02/06/2025 |
5 | Acquisition by John Aballi of 75000 shares of Exagen at 3.58 subject to Rule 16b-3 | 02/21/2025 |
6 | Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 | 02/25/2025 |
7 | Acquisition by John Aballi of 8621 shares of Exagen at 2.465 subject to Rule 16b-3 | 02/28/2025 |
8 | Exagen Inc. Short Interest Update | 03/06/2025 |
9 | Acquisition by Tullis James L L of 9000 shares of Exagen at 16.41 subject to Rule 16b-3 | 03/07/2025 |
10 | Exagen Inc. Reports Q4 Loss, Tops Revenue Estimates | 03/11/2025 |
11 | Exagen Inc Q4 2024 Earnings Call Highlights Record Revenue and Strategic Growth Initiatives | 03/12/2025 |
12 | Are Exagen unfluctuating technical and fundamental indicators contributing to the recent decline | 03/17/2025 |
| Begin Period Cash Flow | 36.7 M |
Exagen |
Exagen Relative Risk vs. Return Landscape
If you would invest 471.00 in Exagen Inc on December 19, 2024 and sell it today you would lose (109.00) from holding Exagen Inc or give up 23.14% of portfolio value over 90 days. Exagen Inc is generating negative expected returns assuming volatility of 8.3836% on return distribution over 90 days investment horizon. In other words, 74% of stocks are less volatile than Exagen, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Exagen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Exagen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Exagen Inc, and traders can use it to determine the average amount a Exagen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0139
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XGN |
Estimated Market Risk
| 8.38 actual daily | 74 74% of assets are less volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Exagen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Exagen by adding Exagen to a well-diversified portfolio.
Exagen Fundamentals Growth
Exagen Stock prices reflect investors' perceptions of the future prospects and financial health of Exagen, and Exagen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Exagen Stock performance.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 65.76 M | ||||
| Shares Outstanding | 17.9 M | ||||
| Price To Book | 6.79 X | ||||
| Price To Sales | 1.16 X | ||||
| Revenue | 55.64 M | ||||
| Gross Profit | 33.11 M | ||||
| EBITDA | (11.14 M) | ||||
| Net Income | (15.12 M) | ||||
| Cash And Equivalents | 76.39 M | ||||
| Cash Per Share | 4.70 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.55 % | ||||
| Current Ratio | 9.30 X | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (13.28 M) | ||||
| Earnings Per Share | (0.83) X | ||||
| Market Capitalization | 64.79 M | ||||
| Total Asset | 44.69 M | ||||
| Retained Earnings | (294.33 M) | ||||
| Working Capital | 22.95 M | ||||
About Exagen Performance
By examining Exagen's fundamental ratios, stakeholders can obtain critical insights into Exagen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Exagen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 40.84 | 21.06 | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.58) | (1.66) |
Things to note about Exagen Inc performance evaluation
Checking the ongoing alerts about Exagen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Exagen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Exagen Inc generated a negative expected return over the last 90 days | |
| Exagen Inc has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 55.64 M. Reported Net Loss for the year was (15.12 M) with profit before taxes, overhead, and interest of 33.11 M. | |
| Exagen Inc has about 76.39 M in cash with (13.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Exagen Inc has a poor financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by insiders | |
| Latest headline from Macroaxis: Are Exagen unfluctuating technical and fundamental indicators contributing to the recent decline |
- Analyzing Exagen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Exagen's stock is overvalued or undervalued compared to its peers.
- Examining Exagen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Exagen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Exagen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Exagen's stock. These opinions can provide insight into Exagen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.